natgillin/translations-raw huggingface dataset:
The fuel gas supply system of a vessel according to claim 2 wherein the boil-off gas from an upper portion of the LNG tank is in thermal communication with LNG while passing through the heat exchanger and then is supplied to the LNG tank. 
Sustav dobave pogonskog plina za brod prema zahtjevu 3, naznačen time da dodatno sadrži: rekondenzator (103) instaliran nizvodno od jedne crpke u vodu za opskrbu pogonskim plinom; i vod za ukapljivanje isparenog plina spojen iz gornjeg dijela spremnika LNG, koji prolazi kroz rekondenzator, te prema spremniku LNG.
Accordingly, the image data decoder 230 may decode encoded data of at least one coding unit corresponding to the each coded depth in the current maximum coding unit by using the information about the partition type of the prediction unit, the prediction mode, and the size of the transformation unit for each coding unit corresponding to the coded depth, and output the image data of the current maximum coding unit. 
HR P20182053 T1 određivač jedinice za kodiranje (120) generira informaciju o veličini jedinice za transformaciju od jedinice kodiranja dubine kodiranja, pri čemu se dobiva barem jedna jedinica za transformaciju, prema veličini transformacijske jedinice, dijeljenjem visine i širine jedinice kodiranja trenutne dubine ili da podatkovna jedinica bude iste veličine kao jedinica kodiranja trenutne dubine 1 transformacija se izvršava na jedinici kodiranja trenutne dubine temeljeno na barem jednoj transformacijskoj jedinici.
Contrary to the oligofructose derived from inulin hydrolysis, this type contains other linkage types in addition to the B-(2→1)-bonds, be it in limited numbers. 
Nasuprot oligofruktozi dobivenoj hidrolizom inulina, ovaj tip sadržava ograničen broj veza druge vrste, povrh f-(2->1) veza.
A compound of the formula: 
PATENTNI ZAHTJEVI Spoj formule:
inducing immune tolerance. The cyclic peptide or pharmaceutical composition of claim 21, wherein said disease where the activity of a B-adrenergic receptor is enhanced is a heart disease or wherein said patient suffers from a heart disease. 
Ciklički peptid, ili farmaceutski pripravak u skladu s patentnim zahtjevom 21, naznačen time što navedena bolest kod koje je pojačana aktivnost B-adrenergičkog receptora je srčana bolest ili gdje navedeni pacijent boluje od srčane bolesti.
Pharmaceutical composition according to claim 5, wherein the dimethylfumarate is contained in a prolonged release matrix portion of a tablet and the one agent selected from teriflunomide, fingolimod and laquinimod is contained in a coating surrounding the matrix portion. 
Kombinacija za uporabu prema zahtjevu 21., naznačena time što je dimetilfumarat sadržan u dijelu matrice tablete s produljenim oslobađanjem i jedno sredstvo odabrano između teriflunomida, fingolimoda i lakvinimoda sadržano je u ovojnici koja okružuje dio matrice.
In one aspect, a genetically modified mouse is provided, comprising a humanization of an endogenous mouse IL-6Ra gene, wherein the humanization comprises a replacement of mouse IL-6Ra ectodomain-encoding sequence with human IL-6Ra ectodomain-encoding sequence at the endogenous mouse IL-6Ra locus. 
Genetički modificirani miš, koji sadrži humanizaciju endogenog mišjeg IL-6Ra gena, naznačen time da se humanizacija sastoji od zamjene mišje IL-6Ra sekvence koja kodira ektodomenu sa ljudskom IL-6Ra. sekvencom koja kodira ektodomenu na lokusu endogenog miša IL-6Ro, te pri čemu je humanizirani IL-6Ra gen pod kontrolom regulacijskih elemenata endogenog miša.
A second pump, preferably an injection pump, is in fluid communication with the small inoculant concentration bottle and the fluid conduit. 
Druga pumpa, najbolje pumpa za ubrizgavanje povezana je s malom bocom koncentriranog inokulanta i sa cjevovodom za fluid.
In order so to do, it is advantageous to provide for the data processing system 7 (see FIG. 3) to comprise a control program 18 equipped with a communication module 19 capable of communicating with a management program 17, typically by way of a network port. 
Da bi se to tako učinilo, poželjno je osigurati da sustav za obradu 7 (vidi sliku 3) sadržava neki upravljački program 18 koji je opremljen s modulom za komuniciranje 19 koji može komunicirati s programom za rukovođenje 17, tipično preko priključka na mrežu.
The present invention relates to organic compounds, their preparation and their use as pharmaceuticals. 
Predloženi izum odnosi se na organske spojeve, njihovu pripravu i njihovu upotrebu kao lijekova.
The method of Claim 1, wherein said at least a portion of said CRISPR locus of said parent bacterial strain and at least a portion of said modified CRISPR locus of said bacteriophage resistant variant strains are compared by sequencing at least a portion of said CRISPR locus and at least a portion of said modified CRISPR locus. 
Postupak prema zahtjevu 1, naznačen time da se navedeni barem dio navedenog CRISPR lokusa navedenog matičnog bakterijskog soja i barem dio navedenog modificiranog CRISPR lokusa navedenih varijanti sojeva rezistentnih na bakteriofage uspoređuju sekvenciranjem barem dijela navedenog CRISPR lokusa i barem dijela navedenog modificiranog CRISPR lokusa.
Protein AI216611_P1 (SEQ ID NO:44) according to the present invention has an amino acid sequence as encoded by transcript AI216611_T1 (SEQ ID NO:42). 
Farmaceutski pripravak naznačen time da sadrži barem jedan CIORF32 polipeptid ektodomene odabran iz skupine koja sadrži: i. -C10RF32 polipeptid ektodomene koji sadrži sekvencu amino kiseline iz SEQ ID NO: 299; ii.
The method of claim 2, wherein the x-ray powder diffraction (XRPD) pattern of the compound of Formula II has further peaks at about 22.5 and 19.5° 2-θ±0.2°±2-θ. 
Spoj prema zahtjevu 4, naznačen time da uzorak difrakcije X-zraka na prahu (XRPD) ima još signale na oko 22,5 i 19,5° 2-θ ± 0,2° 2-θ.
To a suspension of the compound of Example 1 (778 mg, 2.479 mmol) in concentrated sulphuric acid/water 972 µL/1.4 mL, cooled to ice bath temperature, is added a solution of sodium nitrite (188 mg) in water (680 µL). 
U suspenziju spoja iz primjera 1 (778 mg, 2,479 mmola) u koncentriranoj sumpornoj kiselini/vodi 972 ul/1,4 ml, ohlađenu na temperaturu ledene kupelji, doda se otopinu natrijevog nitrita (188 mg) u vođi (680 ul).
In this latter mentioned embodiment the platform may be of generally rectangular shape and one link of each pair of links is provided at a corner of the platform and the other link of each pair of links is provided at a respective opposite corner of the platform. 
Suhi dok u skladu s patentnim zahtjevom 8, naznačen time što platforma ima općenito pravokutan oblik i jedan spojni element od svakog para spojnih elemenata je predviđen na uglu platforme, a drugi spojni element svakog para spojnih elemenata je predviđen na odgovarajućem suprotnom uglu platforme.
The Reinforcement system (29) according to claim 9, wherein the reinforcement contains fibre strands. 
Sustav ojačanja (29) u skladu s prethodnim patentnim zahtjevom, naznačen time što ojačanje sadrži užad od vlakana.
The components of this embodiment of the present invention are advantageously housed inside a supply plug 55 of the hair-dryer 16, schematically shown in dashed lines in fig. 2. 
Komponente izvedbe ovog patenta su pogodno smještene unutar napojnog utikača 55 sušila za kosu 16, shematski prikazanog isprekidanim linijama na sl.2
A peptide consisting of the amino acid sequence according to SEQ ID No. 6 for use in the treatment of cancer. 
Peptid u skladu s patentnim zahtjevom 1, pri čemu se navedeni peptid sastoji od aminokiselinske sekvence prema ID br.
Process according to any of the previous claims, wherein structural elements are arranged inside the mold in order to facilitate the assembly of further elements to the finished product in order to make complex products. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da su strukturni elementi smješteni unutar kalupa kako bi se olakšalo sklapanje daljnjih elemenata na završeni proizvod radi izrade složenijih proizvoda.
the respective upper edge of which is oriented downward toward the conveying elements, with an inclination such that the height of the edges increases in the direction of the respective blade, arranged above the conveying elements; 
- čiji je odgovarajući produljeni gornji rub usmjeren prema dolje i prema navedenim sredstvima za nošenje, s takvim nagibom da se visina navedenih rubova povećava u smjeru napredovanja navedenih sredstava za nošenje,
a characteristic of subsequent contraction and formation of a solid object that represents double simultaneous imprint (2), and 
- < svojstvo naknadnog stezanja i formiranja krutog predmeta koji predstavlja dvostruki istovremeni otisak (2), te
a protein comprising or consisting of, from N-terminal to C-terminal, (a) a fragment consisting of residues 1 to 183 of SEQ ID NO:8, (b) a heterologous polypeptide comprising at least 3 HPV antigens, each HPV antigen originating from a different HPV type; and (c) a fragment consisting of residues 387 to 1705 of SEQ ID NO:8; 
protein koji se sastoji od, od N-kraja do C-kraja, (a) fragmenta koji se sastoji od ostataka 1 do 183 u SEQ ID NO:8, (b) heterolognog polipeptida koji sadrži najmanje 3 HPV antigena E7, gdje svaki HPV antigen potječe iz različitog tipa HPV-a; i (c) fragmenta koji se sastoji od ostataka 387 do 1705 u SEQ ID NO:8;
is chosen from hydrogen, alkyl, aryl, alkylaryl, substituted alkyl, substituted aryl, and substituted alkylaryl. 
je odabran između vodika, alkila, arila, alkilarila, supstituiranog alkila, supstituiranog arila, i supstituiranog alkilarila.
said non-naturally encoded amino acid is linked to said polymer through an oxime linkage. 
FGF-21 polipeptid prema zahtjevu 1, gdje ta aminokiselina koja nije prirodno kodirana je para-acetil-fenilalanin.
For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. 
Za pripremu farmaceutskih pripravaka od spojeva prikazanog izuma, farmaceutski prihvatljive podloge mogu biti bilo krute ili tekuće.
An inhibitor against hepatocyte growth factor receptor, comprising a compound according to Claim 1, a salt thereof or a hydrate of the foregoing. 
Inhibitor protiv receptora hepatocitnog faktora rasta, naznačen time da sadrži spoj prema zahtjevu 1, njegova sol ili hidrat navedenog.
The composition was added to freshly brewed beer, which was subsequently bottled in a 300 mL green glass bottle (Heineken® export, BSN or Rexam bottle 35.5 EB-5 GR). 
Pripravak se doda u svježe vareno pivo, koje se nakon toga puni u 300 mL bocu od zelenog stakla (Heineken? export, BSN ili Rexam bocu 35.5 EB-5 GR).
The components of the hydrogel component are: 
Datum podnošenja europske prijave patenta:
A milling cutter device for the slats (8) of roller shutters. comprising: 
PATENTNI ZAHTJEVI 1. Glodalica za letvice (8) roleta, koja se sastoji od:
The present invention also relates to use of Compound I of the invention, or a salt thereof for treatment of a disease selected from the group consisting of anxiety disorders, affective disorders including depression, sleep disturbances, migraine, neuroleptic-induced parkinsonism, cocaine abuse, nicotine abuse, alcohol abuse and other abuse disorders. 
Uporaba soli prema bilo kojem od zahtjeva 1-8 u pripremi lijeka za liječenje bolesti izabrane iz skupine koja obuhvaća bolest koja uključuje psihotične simptome, anksiozne poremećaje, afektivne poremećaje uključujući depresiju, poremećaje spavanja, migrenu, neuroleptički inducirani parkinsonizam ili ovisnosti npr. o kokainu, nikotinu ili alkoholu.
The device according to claim 2, wherein the second cryptographic engine is used to securely transfer a new generated key from the second integrated circuitry to the first integrated circuitry. 
Uređaj u skladu s patentnim zahtjevom 1, naznačen time što se sredstvo za šifriranje upotrebljava za siguran prijenos novog generiranog ključa iz drugog integriranog kruga (20) u prvi integrirani krug (10).
The process according to claim 7, wherein the B2-adrenoceptor agonist is fomoterol fumarate dihydrate, the corticosteroid is beclometasone dipropionate, and the anti-cholinergic is glycopyrronium bromide or tiotropium bromide. 
Postupak prema patentnom zahtjevu 7, naznačeno time da agonist B2-adrenoceptora jest fomoterol-fumarat dihidrat, kortikosteroid jest beklometazon-dipropionat te antikolinergik jest glikopironijev bromid ili tiotropijev bromid.
The use according to claim 16 or the human antibody or functional fragment thereof for use according to claim 17, wherein the haematological disease is multiple myeloma, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia, or acute lymphocytic leukemia. 
Uporaba prema patentnom zahtjevu 16 ili humano antitijelo ili njegov funkcionalni fragment za uporabu prema patentnom zahtjevu 17, pri čemu je hematološka bolest multipli mijelom, kronična limfocitna leukemija, kronična mijelogena leukemija, akutna mijelogena leukemija ili akutna limfocitna leukemija.
The casing according to claim 1, wherein the fibers of the prepreg strip of the at least one reinforcement ply and/or the fibers of the prepreg plies are made of carbon fibers and/or glass fibers and/or aramide fibers and/or ceramic fibers. 
Omotač (1) prema bilo kojem od zahtjeva 1 do 7, naznačen time, da su vlakna (9) načinjena od ugljičnih vlakana i/ili staklenih vlakana 1/ili aramidnih vlakana i/ili keramičkih vlakana.
The method of claim 47, wherein said synthetic substance, after the chemical reaction for expansion and setting, in confinement conditions occurring during use, has a compressive strength ranging from 0.2 MPa to 2.4 MPa for densities ranging from 50 kg/m3 to 200 kg/m3. 
Postupak prema jednom ili više prethodnih zahtjeva, naznačen time, da spomenuta sintetička tvar (4), nakon kemijske reakcije proširenja i postavljanja, u ograničenim uvjetima koji se javljaju prilikom uporabe, ima čvrstoću zbijanja u rasponu uglavnom od 0,2 MPa do 2,4 MPa za gustoće u rasponu uglavnom od 50 kg/m*do 200 kg/m?.
Use according to embodiment 5 characterized in that the disorder or disease is selected from the group consisting of neuropathic and migraine pain disorders such as allodynia, hyperalgesic pain, phantom pain, neuropathic pain related to diabetic neuropathy and neuropathic pain related to migraine. 
Primjena prema patentnom zahtjevu 22, naznačena time što su neuropatski bol i poremećaji migrenoznog bola izabrani iz grupe koju čine alodinija, hiperalgezija, fantomski bol, neuropatski bol povezan sa dijabetičkom neuropatijom, neuropatski bol povezan sa neuralgijom trigeminusa, i neuropatski bol povezan sa migrenom.
mixing the mixture obtained in step (iii) with the further suspension of the multivalent metal salt in an alcohol phase provided in step iv) to obtain the alcohol-in-oil type emulsion. 
(v) miješanja smjese dobivene u koraku (ili) s dodatnom suspenzijom viševalentne metalne soli u alkoholnoj fazi dodanom u koraku (iv) kako bi se dobilo emulziju tipa alkohol-u-ulju.
The solutions of at least one anti-IL-23p19 antibody of the invention can be prepared by a process that comprises mixing at least one antibody in an aqueous diluent. 
Izolirano IL-23p19 protutijelo prema zahtjevu 1, naznačeno time što sadrži najmanje jednu varijabilnu regiju laganog lanca i najmanje jednu varijabilnu regiju teškog lanca:
Serine (S) or Threonine (T) at heavy chain amino acid position 103; and/or 
(b) -serin (S) ili treonin (T) na aminokiselinskoj poziciji 103 jakog lanca; i/ili
The use according to claim 1, wherein said pharmaceutically acceptable salt is hydrobromide salt 
Spoj za uporabu prema zahtjevu 2, gdje je ta sol kristalična.
The compound of claim 21, wherein X42 is CR44, and R43 and R44 are, independently, selected from the group consisting of —H, methyl, ethyl, propyl, isopropyl, and cyclopropyl. 
Spoj prema zahtjevu 34, pri čemu Xy je CRa4 1 Rag 1 Rag su nezavisno izabrani iz skupine koju čine -H, metil, etil, propil, izopropil i ciklopropil.
A pharmaceutical composition comprising a compound of formula: wherein, n is 0, 1, or 2; 
Spoj prema patentnom zahtjevu 1, naznačen time što je p jednako 0, 1 R;g je C;-Ca alkil.
A nucleic acid molecule encoding an antibody or antigen-binding fragment as defined in any one of Claims 1 to 9, or a component polypeptide chain thereof. 
Molekula nukleinske kiseline naznačena time da kodira protutijelo ili fragment za vezanje antigena kao što je definirano u bilo kojem od zahtjeva 1 do 7.
A method for treatment of a renal disorder, comprising administering an effective amount of a compound of the formula (I) 
Postupak za proizvodnju spojeva formule (I), naznačen time da [A] spoj s formulom (II)
halogen, or (C3-6)cycloalkyl, or and R2 together with the nitrogen atom to which they are attached form a 5 to 7 membered heterocyclic ring containing at least 1 nitrogen atom or 1 nitrogen and 1 additional heteroatom selected from N or O, or 
R:iR, zajedno s atomom dušika na koji su priključeni tvore 5 do 7-člani heterociklički prsten koji sadrži barem 1 atom dušika ili 1 atom dušika i 1 dodatni heteroatom primjerice odabran od N ili O, ili R, je hidroksi i R, je formil;
The construct for the use of claim 7, wherein 5µg per square meter patient body surface area are to be administered at the first day(s) of the infusion period, followed by administration of 15µg per square meter patient body surface area as daily dose for the remaining period. 
Konstrukt za uporabu prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time što se CD19xCD3 konstrukt protutijela bispecifičnog jednostrukog lanca daje u dnevnoj dozi od 15 µg do 30 µg po kvadratnom metru površine tijela pacijenta.
An ODT as claimed in claim 1 or claim 2, further comprising an adhesive agent, wherein the adhesive agent is selected from the group consisting of sucrose aluminum sulfate complex, chitosan and derivatives thereof, polyvinylpyrrolidone, methylcellulose, sodium carboxymethylcellulose, hydroxypropyl cellulose, cross-linked or uncross-linked polyacrylates, cross-linked polyarylates, acidic cross-linked or uncross-linked polyacrylates, polyacrylic acid homopolymers or copolymers, aminoalkyl methacrylate copolymers, methacrylic acid/methylmethacrylate copolymer, alkylacrylate/alkylmethacrylate copolymers, ammoniomethacrylate copolymers, carbomer homopolymers or copolymers, hydrophilic polysaccharide gums, maltodextrins, cross-linked alginate gum gels, polycarboxylated vinyl polymers, pectins, xanthan gums, alginic acid, modified alginic acids, and combinations thereof. 
Tableta za oralno disperziranje sukladno bilo kojem od zahtjeva 1-3, koja nadalje sadrži adheziv, pri čemu je adheziv odabran iz skupine koju čine saharoza aluminijevog sulfata kompleksa, kitozana i njegovih derivata, polivinilpirolidona, metilceluloze, natrij karboksimetil celuloae, hidroksipropil celuloza, umreženih ili neumreženih poliakrilata, umreženi poliarilata, kiselih umreženi ili neumreženi poliakrilat, homopolimer ili kopolimer poliakrilne kiseline, aminoalkil metakrilatnih kopolimer, kopolimer metakrilne kiseline/metilmetakrilat, kopolimer alkilakrilat/alkitmetakrilat, amoniometakrilatnih kopolimer, karbomernih homopolimer ili kopolimer, hidrofilne polisaharidne gume, maltodekstrin, gelov umrežene alginatne gume, polikarboksilirane vinilne polimere, pektina, ksantanske gume, alginske kiseline, modificirane alginske kiseline ili njihovih kombinacija.
In another embodiment, the invention also features an oral formulation comprising about 90-120 mg of a 9-aminomethyl tetracycline compound, e.g., 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof and a pharmaceutically acceptable carrier. 
Oralna formulacija u obliku tablete 9-[(2,2-dimetilpropilamino)metiljminociklina ili njegove soli, naznačena time što sadrži 18 do 22%, težinski, 9-[2,2-dimetilpropilamino)metillminociklina, te što je tableta oblikovana postupkom kompaktiranja valjkom.
Various taxane compounds are known to exhibit anti-tumor activity. 
Poznati su razni spojevi taksana koji pokazuju anti-tumorsku aktivnost.
The composition of claim 1, wherein the at least one pharmaceutically acceptable excipient is selected from mannitol, microcrystalline cellulose, crospovidone, and magnesium stearate. The composition of claim 1, which further comprises a permeation enhancer. 
Farmaceutski pripravak za upotrebu prema zahtjevu 5, naznačen time što pripravak nadalje sadrži pomoću tvar odabranu od manitola, mikrokristalne celuloze, krospovidona, i magnezijevog stearata, ili pri čemu pripravak nadalje sadrži pojačivač permeabilnosti.
The mouse of claim 2, wherein the human FcYRIIIA is expressed on NK cells of the mouse. 
Miš prema zahtjevu 2, naznačen time, što se humani FcyRIIA izražava na NK stanicama miša.
a compound defined by the formula 1 wherein 
1. = Spoj definiran formulom 1 OF ČH, 1
The compounds of the first aspect of this invention (especially in the acid form) are very potent inhibitors, typically selective inhibitors, of GST P1-1. 
Spojevi prvog aspekta ovog izuma (posebno u obliku kiseline) su inhibitori, tipično selektivni inhibitori, GST P1-1.
The method of aspect 3, wherein the MASP-1 inhibitory agent is a MASP-1 monoclonal antibody, or fragment thereof, that specifically binds to a portion of SEQ ID NO:10. 
(i) -monoklonskog protutijela protiv MASP-I, ili njegovog fragmenta, koje se specifično veže na dio SEQ ID NO:10;
The method according to claim 1, wherein the plurality of billing parameters includes a credit card number or a bank account identifier and the billing includes at least one of billing the credit card associated with the credit card number and billing the bank account associated with the bank account identifier. The method according to claim 1, further comprising: 
Metoda prema jednom ili više prethodnih patentnih zahtjeva, pri čemu navedenih mnoštvo parametara naplate sadrže broj kreditne kartice ili identifikator bankovnog računa a navedeni korak naplate obuhvaća naplatu kreditne kartice povezane sa navedenim brojem kreditne kartice ili naplatu bankovnog računa povezanog sa navedenim identifikatorom bankovnog računa.
Either the monoclinic form, or the orthorhombic form or a mixture of polymorphs was obtained after micronization starting with the monoclinic form. 
Dobiven je monoklinski oblik, ili ortorombski oblik, ili smjesa polimorfa nakon mikronizacije koja je započela s monoklinskim oblikom.
The pressurized metered dose inhaler according to claim 19, wherein metering valve is capable of delivering a volume of 50 or 63 µl. 
Inhalator sa stlačenim inhalatom prema patentnom zahtjevu 17, naznačen time da je odmjerni ventil sposoban isporučiti volumen od 50 ili 63 µl.
A method of treating a Pneumovirinae virus infection in a mammal in need thereof comprising administering to the mammal a therapeutically effective amount of a compound as described in claim 1, or a pharmaceutically acceptable salt thereof. 
Spoj kao što je opisano u bilo kojem od zahtjeva 1-20, ili njegova farmaceutski prihvatljiva sol, za upotrebu u medicinskoj terapiji, kao što je za upotrebu u terapeutskom ili profilaktičkom liječenju infekcije virusom Pneumovirinae ili infekcije sa respiratornim sincicijalnim virusom.
A system according to claim 3, wherein the pump for the circulation of the hot liquid fluid in the preheating hydraulic circuit (112) comprises a second pump (P 2) which can be activated alternatively to the recirculation pump (P 1). 
Sustav prema zahtjevu 3, gdje je pumpa za cirkuliranje tekućine u krugu za prethodno zagrijavanje (112) sastavljena od druge pumpe (P2) koja se može alternativno aktivirati u odnosu na recirkulacijsku pumpu (P1).
A method according to claim 48, further comprising the step of preparing a unit dosage form from the composition. 
Postupak u skladu sa zahtjevom 48, naznačen time, da nadalje obuhvaća korak izrade jediničnog dozirnog oblika pripravka.
A compound comprising a modified oligonucleotide consisting of 16 linked nucleosides having a nucleobase sequence consisting of the sequence recited in SEQ ID NO: 598, wherein the modified oligonucleotide comprises: 
Spoj koji obuhvaća modificiran oligonukleotid koji se sastoji od 16 vezanih nukleozida koji imaju nukleobaznu 25